Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT00707304 Completed - Clinical trials for Non Small Cell Lung Cancer

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

FORTIS-M
Start date: November 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.

NCT ID: NCT00707252 Terminated - Clinical trials for Non-Small Cell Lung Cancer

Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to study if the addition of the green tea extract, Polyphenon E, to Erlotinib is safe and if it has potential to improve outcomes in second line therapy for Advanced Stage IIIb/IV Non-small cell lung cancer.

NCT ID: NCT00706862 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

FORTIS-C
Start date: February 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone

NCT ID: NCT00705549 Terminated - Clinical trials for Non-Small-Cell Lung Cancer

Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

Start date: February 2008
Phase: Phase 2
Study type: Interventional

This is a prospective pilot phase II trial, in patients with wet stage IIIb and IV NSCLC using chemotherapy regimens which will be defined according to the pharmacogenomic profile (tumoral expression of ERCC1, BRCA1 and RRM1) of the tumor cells.

NCT ID: NCT00702975 Completed - NSCLC Clinical Trials

Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

Start date: September 2008
Phase: Phase 2
Study type: Interventional

A phase II study of combination therapy of carboplatin -gemcitabine plus bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior chemotherapy.

NCT ID: NCT00702962 Terminated - Clinical trials for Small Cell Lung Cancer

Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer

Start date: September 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase I portion of the study is to assess the maximum tolerated dose of vorinostat when combined with carboplatin plus etoposide. The Phase II portion is to determine progression-free survival among patients with extensive disease small cell lung cancer receiving carboplatin plus etoposide with vorinostat.

NCT ID: NCT00702572 Terminated - Clinical trials for Non-small Cell Lung Cancer

Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer

Start date: April 2008
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated advanced non-small cell lunc cancer.

NCT ID: NCT00702182 Completed - Clinical trials for Non-Small Cell Lung Cancer

Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer

Start date: April 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to define the schedule and dose of oral vinorelbine (Navelbine) to be used with erlotinib in non-small cell lung cancer.

NCT ID: NCT00701870 Terminated - Clinical trials for Non-small Cell Lung Cancer

Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non‑Small Cell Lung Cancer

Start date: October 2008
Phase: Phase 2
Study type: Interventional

TLK199.2102 was a multicenter Phase 2 randomized study to determine the effect of Telintra treatment on chemotherapy induced neutropenia (CIN) in patients with non small cell lung cancer receiving first‑line therapy with carboplatin and docetaxel.

NCT ID: NCT00701558 Completed - Clinical trials for Non-Squamous Non-Small Cell Lung Cancer

A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer.

Start date: August 2008
Phase: Phase 2
Study type: Interventional

This single arm study will assess the efficacy and safety of Tarceva + gemcitabine in chemotherapy-naive patients with unresectable, advanced and/or metastatic non-small cell lung cancer. Patients will receive Tarceva 150mg po daily, in combination with gemcitabine 1000mg/m2 i.v. weekly for 3 weeks of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is <100 individuals.